Opioid-Induced Neurotoxicity Management

Clinical Presentation and Diagnosis

Opioid-induced neurotoxicity manifests as a spectrum of CNS toxicity including drowsiness, cognitive impairment, confusion, hallucinations, myoclonic jerks, and—in severe cases—seizures and opioid-induced hyperalgesia/allodynia, according to the American Society of Clinical Oncology 1, 2.
The syndrome results from accumulation of toxic opioid metabolites, particularly in the setting of escalating doses, renal impairment, or dehydration, as stated by the European Society for Medical Oncology 1.
When CNS toxicity symptoms like myoclonic jerks and seizures occur, they are specifically caused by toxic metabolite accumulation rather than the opioid's primary analgesic mechanism, as reported by the American Society of Clinical Oncology 1, 2.

Administer parenteral midazolam infusion immediately for active seizures or severe myoclonus, as recommended by the Neuro-Oncology society 5, 6.
Switch to an alternative opioid agonist and/or route immediately, as this allows titration to adequate analgesia without the same disabling effects, according to the American Society of Clinical Oncology 1, 2.
Start levetiracetam or lacosamide as these agents do not significantly impact hepatic metabolizing enzymes, as stated by the American Academy of Neurology 5, 6.

Correct metabolic derangements including hypokalemia, hypomagnesemia, and hypocalcemia, as recommended by the Endocrine Society 4.
Hyponatremia with neurological symptoms requires immediate 3% hypertonic saline with target correction of 6 mmol/L over 6 hours, according to the European Society of Endocrinology 4.

Anti-seizure medications should not be used as primary prophylaxis among patients with brain metastases without prior seizures, as stated by the American Society of Clinical Oncology 5, 7.
Dexamethasone 4-8 mg/day would be indicated for symptomatic brain metastases with mass effect, as recommended by the American Academy of Neurology 5, 7.